Subject(s)
Drug Eruptions/etiology , Interferon-alpha/adverse effects , Skin Diseases, Vesiculobullous/chemically induced , Adult , Drug Eruptions/pathology , Hepatitis C/drug therapy , Hepatitis, Chronic/drug therapy , Humans , Injections, Intramuscular , Interferon alpha-2 , Interferon-alpha/therapeutic use , Male , Recombinant Proteins , Skin Diseases, Vesiculobullous/pathologyABSTRACT
A total of 188 acne patients (113 male and 75 female) with a mean age of 25 years (range 15-42 years) were treated with isotretinoin in doses ranging from 0.5 to 1 mg/kg. The study lasted 9 years. The treatment was not terminated until 2 months after total healing. The patients were then re-examined at regular intervals. In the event of a recurrence greater than grade 2 (pre-nodular threshold grade), they underwent a new course of treatment. At the end of the study, three groups were distinguished: (1) immediate, long-term, stable remissions following one single course of isotretinoin (111 patients with an average follow-up period of 27 months); (2) stable remissions following 2 or 3 courses of isotretinoin (54 patients with an average follow-up period of 16 months); (3) immediate partial remissions or partial remissions following several courses of treatment in 23 patients who continued to present with at least grade 3 acne. There was no significant statistical difference between the first two groups with respect to the age and sex of the patients and the grade and prior duration of the acne. The third group differed from the other two in having a greater proportion of patients with microcystic acne (p < 0.05) and women with endocrinological problems ((p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Acne Vulgaris/drug therapy , Isotretinoin/therapeutic use , Acne Vulgaris/classification , Adolescent , Adult , Amenorrhea/complications , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Isotretinoin/administration & dosage , Male , Prospective Studies , Recurrence , Remission Induction , Sex Factors , Time FactorsABSTRACT
37 women have received during a total of 429 cycles (mean 12 cycles/patients) an association containing cyproterone acetate 2 mg and ethinyl estradiol 0.05 mg. A marked improvement in the clinical symptoms (acne 35 cases) has been observed. The sequential determination of the sebum excretion rate has been made in the same time (150 measurements) and revealed an important, early and durable decrease in the sebum excretion rate. The respective role of the CA and EE has been analysed in a second trial. It seems that the antiandrogen might play a role in the clinical improvement and in the reduction of the sebaceous flow.
